Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants

Key facts

Sponsor

Stanford University

Principal Investigator

Vinod K Bhutani, MD

Stanford University

Intervention

Bilirubin Binding Capacity(diagnostic_test)

Enrollment

143 enrolled

Eligibility

All sexes

Timeline

2016 – 2018

Study locations (1)

• Lucile-Packard Children's Hospital at Stanford, Stanford, California, United States

Collaborators

Smith-Kettlewell Eye Research Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Bilirubin encephalopathy

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT04584983
  Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration
  The University of Texas Health Science Center, Houston

See all trials for Bilirubin encephalopathy →